| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Paula Soteropoulos is Director at QURE, with reported holdings spanning 3 companies. Paula Soteropoulos's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $586K at current prices.
Our model assigns Paula Soteropoulos a strong insider score of 75/100, based on 11 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +37.6%.
Paula Soteropoulos's largest disclosed position is in QURE as Director, worth about $482K. The QURE filings lean toward selling, a net 48,578 shares.
Paula Soteropoulos has 35 Form 4 filings on record from January 2017 to October 2026, across 3 companies: Director at Rallybio (RLYB), 2022–2026; Director at Dianthus Therapeutics (DNTH), 2023–2026; Director at uniQure (QURE), 2017–2024.
The 56 reported transactions were 22 open-market sales, 18 option or other derivative awards, 9 option exercises and 7 stock awards.
Counted by filing, the open-market trades come to no purchases and 18 sales worth about $4.2M.
The largest open-market sale was 27,594 shares of DNTH at an average $78.05 on March 24, 2026, about $2.2M.
3 of the 5 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | DNTH Dianthus Therapeutics, Inc. | Director | Sale+OE10b5-1 | 599 | $85.47 | $51,196.53 | - | +26.8% | - | |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. | Director | Sale+OE10b5-1 | 599 | $80.11 | $47,985.89 | - | +14.0% | - | |
| Mar 24, 2026 | DNTH Dianthus Therapeutics, Inc. | Director | Sale+OE10b5-1 | 27,594 | $78.05 | $2,153,711.70 | - | +11.2% | - | |
| Jun 13, 2024 | QURE Uniqure N.V. | Director | Sell | 2,220 | $5.14 | $11,410.80 | -9.9% | +4.2% | +192.2% | |
| Jun 16, 2023 | QURE Uniqure N.V. | Director | Sell | 2,275 | $18.99 | $43,202.25 | -9.2% | -60.6% | -74.9% | |
| Feb 27, 2023 | QURE Uniqure N.V. | Director | Sell | 384 | $19.97 | $7,668.48 | -2.3% | -8.4% | -67.9% | |
| Jan 18, 2023 | QURE Uniqure N.V. | Director | Sale+OE | 6,000 | $22.59 | $135,540.00 | -26.8% | -12.7% | -75.0% | |
| Dec 14, 2022 | QURE Uniqure N.V. | Director | Sale+OE | 6,800 | $23.44 | $159,384.00 | -29.3% | -15.4% | -65.6% | |
| Nov 29, 2022 | QURE Uniqure N.V. | Director | Sale+OE | 6,200 | $25.38 | $157,356.00 | -27.5% | -18.3% | -73.5% | |
| Feb 28, 2022 | QURE Uniqure N.V. | Director | Sell | 596 | $16.87 | $10,054.52 | -7.5% | -15.5% | +23.4% |